Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Core Insights - Relay Therapeutics, Inc. is a clinical-stage company focused on developing small molecule precision medicine therapies for cancer and genetic diseases [3] Group 1: Company Overview - Relay Therapeutics is developing potentially life-changing therapies for patients with cancer and genetic diseases [3] - The company's lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer [3] - Relay's pipeline includes programs targeting NRAS-driven solid tumors and Fabry disease, in addition to zovegalisib's investigation in PI3Kα-driven vascular anomalies [3] Group 2: Upcoming Events - Management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 10:30 a.m. ET [1] - The fireside chat will be webcast live and accessible through Relay Therapeutics' website, with an archived replay available for 30 days post-event [2]